Kramer Michal, Brichova Michaela, Tugal-Tutkun Ilknur, Panchenko Mykola, Gormezano Natali, Koenigsbauer Franziska, Franco Pablo, Muccioli Cristina, Hasanreisoglu Murat
Department of Ophthalmology, Rabin Medical Center, Petach Tikva and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Department of Ophthalmology, Charles University and General University Hospital, Prague, Czech Republic.
Ophthalmol Ther. 2021 Sep;10(3):565-580. doi: 10.1007/s40123-021-00351-4. Epub 2021 Jun 12.
The EyeCOPE study characterized noninfectious intermediate posterior, or panuveitis (NIIPPU) before biologic agents were widely available.
This retrospective, observational study included adults with NIIPPU attending a routine ophthalmological visit. Data were collected from the study visit and medical records.
Of 565 patients, 58.8% were female, and the mean age was 41.3 years; 33.8% had idiopathic uveitis and 45.8% had panuveitis. The median time from symptom onset to diagnosis and treatment was 27.0 and 30.5 days, respectively. Patients received immunosuppressants and systemic/local corticosteroids. Most patients experienced substantial decline in ocular function (mean best corrected visual acuity, 0.4 logMAR). Mean total work productivity impairment among employed patients was 31.0%. Most patients reported ocular complications (70.8%) such as vision loss and cataracts.
Despite treatment, most patients with NIIPPU experienced a decline in ocular function and ocular complications. There is an unmet need for additional NIIPPU treatment, such as targeted monoclonal antibodies.
EyeCOPE研究对在生物制剂广泛应用之前的非感染性中间部、后部或全葡萄膜炎（NIIPPU）进行了特征描述。
这项回顾性观察研究纳入了前来进行常规眼科检查的NIIPPU成年患者。数据从研究访视和病历中收集。
在565例患者中，58.8%为女性，平均年龄为41.3岁；33.8%患有特发性葡萄膜炎，45.8%患有全葡萄膜炎。从症状出现到诊断和治疗的中位时间分别为27.0天和30.5天。患者接受了免疫抑制剂和全身/局部皮质类固醇治疗。大多数患者的眼部功能出现了显著下降（平均最佳矫正视力，0.4 logMAR）。就业患者的平均总工作生产力损害为31.0%。大多数患者报告了眼部并发症（70.8%），如视力丧失和白内障。
尽管进行了治疗，但大多数NIIPPU患者的眼部功能仍出现下降且伴有眼部并发症。对额外的NIIPPU治疗，如靶向单克隆抗体，仍有未满足的需求。
